TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01996917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prineo
Description: After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
Study: NCT05865938

Intervention type: DEVICE
Intervention: PASCAL vs. MitraClip
Description: transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device.

Intervention type: DEVICE
Intervention: PASCAL vs. MitraClip
Description: transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device.
Study: NCT03806348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuturing
Description: Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
Study: NCT02993588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 6 mg tablet once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once daily
Study: NCT01884441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
Study: NCT01052246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination of clindamycin 1% + benzoyl peroxide 5%
Description: Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm
Study: NCT02492048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellutome Epidermal Harvesting System
Description: Cellutome Epidermal Harvesting System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split Thickness Skin Graft
Description: Split Thickness Skin Graft
Study: NCT00986466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise and vitamin D supplementation
Description: 20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: 20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: placebo per day for two years no supervised training (maintenance of their current level of physical activity)
Study: NCT02511613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squalamine Lactate Ophthalmic Solution, 0.2%
Description: Squalamine Lactate Ophthalmic Solution, 0.2% administered BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution, administered BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab intravitreal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab intravitreal injection
Study: NCT00566527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad® manufactured with recombinant Human Albumin (rHA)
Description: A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
Study: NCT02354911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoregulatory Dendritic Cells
Description: Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Control
Description: Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
Study: NCT02334241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbact®
Description: Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best local cares
Description: Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
Study: NCT03083977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: The intervention features music processed based on the resonating frequencies of the middle ear
Study: NCT01279252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole, clarithromycin, ciprofloxacin and lansoprazole
Study: NCT04528888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
Study: NCT00933283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
Study: NCT01574664

Intervention type: DEVICE
Intervention: RFID Tag (Health Beacon)
Description: The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette
Study: NCT00906061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
Study: NCT00000395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folinic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Study: NCT00566527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad® manufactured with recombinant Human Albumin (rHA)
Description: A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad® manufactured with recombinant Human Albumin (rHA)
Description: A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
Study: NCT00959946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
Study: NCT03925558

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00903227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Evohaler pMDI
Description: One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Evohaler pMDI
Description: One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of inhaled Placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of inhaled Placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of inhaled Placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Evohaler
Description: One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intranasal spray
Description: placebo intranasal spray 2 squirts each nostril once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intranasal spray
Description: placebo intranasal spray 2 squirts each nostril once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (Flixonase®)
Description: intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
Study: NCT02971488

Intervention type: OTHER
Intervention: Screening for HCV in PWID and Linkage-To-Care
Description: Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population.
Study: NCT01323777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study: NCT00981968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan sodium/Placebo
Description: 100 mg and 200 mg, tablet, single and multiple oral doses for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan sodium/Placebo
Description: 100 mg and 200 mg, tablet, single oral dose
Study: NCT04202393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment Adherence Program (ITAP)
Description: Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Assessment and Follow-up Evaluation (SAFE)
Description: Enhanced assessment and evaluation with clinician feedback.
Study: NCT00159783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine, 40 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 40 weeks
Study: NCT03104387

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electric train
Description: Exposure to air with low level of ultrafine particles (Electric train)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel train
Description: Exposure to air with high level of ultrafine particles (Diesel train)
Study: NCT02709655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Description: 10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20mg/day
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablet, orally
Study: NCT01006824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Capsule endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dedicated small bowel contrast radiography
Description: Dedicated small bowel contrast radiography
Study: NCT02220816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive training
Description: 30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Competitive Training
Description: 30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
Study: NCT03107806

Intervention type: DEVICE
Group type: OTHER
Intervention: OptiScanner®
Description: 1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®

Intervention type: DEVICE
Group type: OTHER
Intervention: OptiScanner®
Description: 1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®
Study: NCT04716855

Intervention type: OTHER
Intervention: Quality of life and daily living activities assessment tests
Study: NCT00468910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT04569331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation of efferent loop
Description: Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation pelvic floor
Description: 3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
Study: NCT01734486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.9 UI/kg/week. Subcutaneous injection for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 1.8 UI/kg/week. Subcutaneous injection for 3 years
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette
Study: NCT02622100

Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Study: NCT02607254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
Study: NCT04825145

Intervention type: OTHER
Intervention: Pregnancy
Description: Pregnancies complicated by preeclampsia
Study: NCT00441441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: fluticasone propionate 100mcg HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: fluticasone propionate/salmeterol 100/50mcg HFA
Study: NCT02929849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg SC
Description: Salacia (T1) capsule given with breakfast (mixed meal tolerance test)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg SC
Description: Salacia (T2) capsule given with breakfast (mixed meal tolerance test)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given with breakfast (mixed meal tolerance test)